An interventional study of Educational and Training with counselling in COPD, ILD and Dyspnea, sponsored by Air Liquide Healthcare Spain. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-31.
Sponsored by Air Liquide Healthcare Spain (part of Air Liquide) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain — 42 open to participants now, 45 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Spain.
Among the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, this one is the 224th largest by enrollment of the 238 interventional ones that give a count, is one of 15 that started in 2019, is one of 68 with no phase, and was the 240th registered.
5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 859 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →42 of the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in Spain, United States, Denmark and 6 more countries
Ages 18–80
Aether Tech S.L. · Sites in Spain
Ages 40–90
Pfizer · Sites in Spain, United States, Argentina and 15 more countries
Ages 35–80
Hospital Universitario La Paz · Sites in Spain
Ages 45–75
Clinica Universidad de Navarra, Universidad de Navarra · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 562 Pulmonary Disease, Chronic Obstructive studies recruiting now, 308 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
309 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 97 · Phase 4 40
First in 2000; this study’s year is marked. 15 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 62 across 3,846 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 336 across the 238 interventional studies, 254 across the 70 observational. Of the 217 that completed or were terminated, 112 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
169 of 309 have an industry lead sponsor. The 10 most frequent:
This study is registered under Air Liquide Healthcare Spain, one of the names counted as Air Liquide. Under that name alone:
Air Liquide Healthcare Spain is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Air Liquide has 9 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
12 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT07679646Air Liquide Healthcare SpainEffectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO) | 2026-12 |
| NCT07432191Iconic Solutions By Murcia SLMedical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning. | 2026-12 |
| NCT07938086Aether Tech S.L.Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk Test | 2026-12-20 |
Add all 12 to your calendar (.ics) → With an account.
Among the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pilot study with patients with prescription of portable oxygen therapy, to test the impact on adherence of a patient-centered empowerment program, with contents on the nature of the respiratory pathology, the symptom of dyspnea, the benefits of the therapy, adjustment expectations and beliefs, as well as health habits.
All patients were summoned to the care center, being evaluated individually by a nurse, and based on the results, a care plan adapted to the specific needs and objectives was initiated. This care plan involved monitoring using different channels (face-to-face, telephone), with the main objective of monitoring the evolution of compliance, adherence and improving the quality of life of patients. The interventions that were carried out were educational and formative (using counseling communication skills), and technological (using monitoring tools in specific cases). The empowerment program was an educational session in which the nurse discussed content about dyspnea, the benefits of therapy, etc.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients were summoned to the care center, being evaluated individually by a nurse, and based on the results, a care plan adapted to the specific needs and objectives was initiated. This care plan involved monitoring using different channels (face-to-face, telephone), with the main objective of monitoring the evolution of compliance, adherence and improving the quality of life of patients. The interventions that were carried out were educational and formative (using counseling communication skills), and technological (using monitoring tools in specific cases). The empowerment program was an educational session in which the nurse discussed content about dyspnea, the benefits of therapy, etc.
Behavioral: Educational and Training with counselling
The nurse conducts a structured interview that covers the following areas: information on respiratory attraction and the symptom of dyspnea, expectations and beliefs about oxygen therapy, use of oxygen therapy, healthy habits, social support. It also evaluates the patient's perception of oxygen therapy, and the level of dyspnea using the mMRC scale. After this, the nurse evaluates the current level of adherence, and if she considers that the patient needs a reinforcement session, she schedules a workshop with 3 other patients and their main caregivers. This workshop takes place 30 days after this interview. In other patients, depending on the level of adherence, a support call is made, and all patients are visited again at the center at 90 days, performing the same evaluation with a structured interview and the scales that were made on day 1
Adherence - Changes
Number of hours of use of oxygen concentrator / day
Time frame: Day 1 and Day 90
Dyspnea - Changes
Level of dyspnea, measured with the mMRC scale. Minimum score: 0, Maximum score: 4. A high score implies a worse outcome.
Time frame: Day 1 and Day 90
Quality of Life - Changes
General well-being state, measured with a visual analog scale. Minimum score: 0, Maximum score: 10. A high score implies a better outcome.
Time frame: Day 1 and Day 90
Emotional State - Changes
Mood, measured with a 3 level likert item . Minimum score: 0, Maximum score: 2. A high score implies a better outcome.
Time frame: Day 1 and Day 90
Activities
Level of activity. measured with a 3 level likert item . Minimum score: 0, Maximum score: 2. A high score implies a better outcome.
Time frame: Day 1 and Day 90
Social Relations
Level of social activity. measured with a 3 level likert item . Minimum score: 0, Maximum score: 2. A high score implies a better outcome.
Time frame: Day 1 and Day 90
Plan to share: Yes — Clinical impact, assistance and / or technological development. This project has a great impact and clinical and technological significance. From the clinical point of view, the aim is to identify the patient in order to better serve him and ensure adherence to one of the treatments where it is more complex to achieve patient compliance. Bibliometric impact. This project is expected to lead to world-class, high-impact publications.
Time frame: 36 months after the publication of the work in a research journal
Access criteria: Researchers who want to replicate the study
Ran from Mar 2019 to primary completion in Apr 2019, 1 month.
Of 88 industry-sponsored interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's 1 month is below that.
Counting every sponsor, half of 1,186 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Air Liquide Healthcare Spain →